ConductScience.org, home

Comparison · NCT01876082-deaths

PAZOPANIB vs Vinblastine and Methotrexate: deaths from any cause

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

2 sourcestrial-comparisons-2026-03-23-0.1.0

Download JSON
Cite this record

ConductScience Library. PAZOPANIB vs Vinblastine and Methotrexate: deaths from any cause. Trial comparisons, record NCT01876082-deaths. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT01876082-deaths

On this page

Measures6

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

MeasureValue95% interval, lower95% interval, upperMethodNote
Risk in group 10.02080.003690.109wilson
Risk in group 2000.149wilson
Risk difference, group 1 minus group 20.0208-0.1290.109newcombe hybrid score
Risk ratio, group 1 over group 2loga group has no participants with the outcome
Odds ratio, group 1 over group 2loga cell of the two-by-two table is zero
Number needed to harm, for one more death from any cause on PAZOPANIB than on Vinblastine and Methotrexate48from the risk difference intervalthe interval includes no difference

Groups2

Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.

GroupTitleDescriptionWith the outcomeAnalysedClinicalTrials.gov code
Group 1PAZOPANIB
Pazopanib~* 800 mg per day~* oral administration~* at least 1 hour before or 2 hours after a meal,~* until disease progression or for 12 months maximum~PAZOPANIB treatment: Pazopanib~* 800 mg per day~* oral administration~* at least 1 hour before or 2 hours after a meal,~* until disease progression or for 12 months maximum
148EG000
Group 2Vinblastine and Methotrexate
vinblastine 5 mg / m², methotrexate 30 mg / m (J1, J8, J15, J21, 6 months and then J1, J15) 28 days per cycle until disease progression or for 12 months.~Active Comparator: Vinblastine and Methotrexate: Active Comparator: Vinblastine and Methotrexate vinblastine 5 mg / m², methotrexate 30 mg / m (J1, J8, J15, J21, 6 months and then J1, J15) 28 days per cycle until disease progression or for 12 months.
022EG001

Harm

What it counts
Total, all-cause mortality
Time frame
2 years

Source ClinicalTrials.gov

Trial

Title
PAZOPANIB Efficacy and Tolerance in Desmoids Tumors
NCT number
NCT01876082
Phases
PHASE2
Conditions
Progressive Desmoids Tumors
Interventions
PAZOPANIB treatment, Active Comparator: Vinblastine and Methotrexate
Lead sponsor
Institut Bergonié
Results first posted
2021-03-05

Source ClinicalTrials.gov

Source

Release
trial-comparisons-2026-03-23-0.1.0
Release manifest SHA-256
f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
AACT copy
2026-03-23
Tables read
outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet

Source ClinicalTrials.gov

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

For software

Read this comparison from software.

The record is JSON. No key.

GET https://conductscience.org/api/comparisons/v1/NCT01876082-deaths